Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats

Experimental Neurology

Volumn 175, Issue 1, 2002, Pages 257-274

  Meshul, Charles K ^a,b   Kamel, Darlene ^a   Moore, Cindy ^a   Kay, Tom S ^a   Krentz, Lisa ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Contralateral rotations; Electron microscopy; Glutamate synapses; Immunocytochemistry; Nicotine; Parkinson's disease

Indexed keywords

APOMORPHINE; GLUTAMIC ACID; NICOTINE; OXIDOPAMINE; SODIUM CHLORIDE;

AMINO ACID BRAIN LEVEL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG EFFICACY; MALE; NERVE ENDING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ROTATION; SYNAPTIC MEMBRANE;

EID: 0036250065     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2002.7900     Document Type: Article

References (77)

1. The functional anatomy of basal ganglia disorders
2. Nicotine-induced release of catecholamines from rat hippocampus and striatum
3. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity
4. Desensitisation of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine
5. Reduction of apomorphine-induced rotational behaviour by subthalamic lesion in 6-OHDA lesioned rats is associated with a normalization of firing rate and discharge pattern of pars reticulata neurons
6. Transection of corticostriatal afferents reduces amphetamine- and apomorphine-induced striatal Fos expression and turning behaviour in unilaterally 6-hydroxydopamine-lesioned rats
7. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons
8. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra
9. Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking
10. Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens
11. Biochemical evidence for the presence of presynaptic receptors on dopamine nerve terminals
12. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats
13. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions
14. Nicotine alone and in combination with L-DOPA methyl ester or the D2 agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys
15. Identification of synaptic terminals of thalamic or cortical origin in contact with distinct medium-size spiny neurons in the rat neostriatum
16. Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo
17. Changes in apomorphine pharmacodynamics following repeated treatment in 6-hydroxydopamine-lesioned rats
18. Effects of nicotine on dopaminergic nigrostriatal axons requires stimulation of presynaptic glutamatergic receptors
19. Induction of long-term potentiation is associated with an increase in the number of axospinous synapses with segmented postsynaptic densities
20. 14C]nicotine
21. Nicotinic receptors in the rat pre-frontal cortex: Increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission
22. Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors
23. 14C-dopamine in rat brain striatum and hypothalamus slices
24. Subsynaptic plate perforations: Changes with age and experience in the rat
25. Parkinson's disease: Prospects for improved therapy
26. Characterization of antisera to glutamate and aspartate
27. Circling behaviour in 6-hydroxydopamine-lesioned rats given pulsed levodopa is reduced more by lesions in the entopeduncular nucleus/substantia nigra pars reticulata than in the subthalamic nucleus
28. Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway
29. Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection
30. 2 receptor upregulation induced by a partial meso-diencephalic hemitransection in the rat
31. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitransection: An analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat
32. The effect of calcium on acetylcholine release from motor nerve terminals
33. 1 receptor and is dependent on NMDA stimulation
34. Nicotinic receptors mediate the release of amino acid neurotransmitters in cultured cortical neurons
35. Nicotine prevents experimental Parkinsonism in rodents and induces striatal increase of neurotrophic factors
36. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studies by in vivo microdialysis: Comparison of naïve and chronic nicotine-treated rats
37. Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals
38. The organization of the projection from the cerebral cortex to the striatum in the rat
39. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats
40. Haloperidol-induced synaptic changes in striatum are associated with glutamate synapses
41. Activation of corticostriatal pathway leads to similar morphological changes observed following haloperidol treatment
42. Time-dependent changes in striatal glutamate synapses following a 6-OHDA lesion
43. Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion
44. Alterations in striatal glutamate synapses following a lesion of the cortico- and/or nigrostriatal pathway
45. 3H]glutamic acid release by dopaminergic drugs
46. Cigarette smoking and protection from Parkinson's disease
47. Reevaluation of the striatal role in the expression of turning behavior in the rat model of Parkinson's disease
48. Plasticity of neorstriatal dopamine receptors after nigrostriatal injury: Relationship to recovery of sensorimotor functions and behavioral supersensitivity
49. Chronic L-dopa alters striatal NMDA receptors in rats with dopaminergic injury
50. Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihyroxyphenyalanine in the "Hemiparkinsonian" rat
51. Chronic nicotine treatment eliminates asymmetry in striatal glucose utilization following unilateral transection of the mesostriatal dopamine pathway in rats
52. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys
53. Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice
54. Techniques to optimize post-embedding single and double staining for amino acid neurotransmitters
55. Nicotine activates and desensitizes midbrain dopamine neurons
56. Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission
57. 3H]dopamine release from striatal synaptosomes: Pharmacological characterization
58. Evidence that the substantia nigra is a site of action for L-DOPA
59. Evidence that L-Dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms
60. Blockade of NMDA receptors by MK-801 reverses the changes in striatal glutamate immunolabeling in 6-OHDA lesioned rats
61. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: A microdialysis study in freely moving rats
62. Activation of dopamine receptors inhibits calcium-dependent glutamate release from corticostriatal terminals in vitro
63. Evidence for functional activity of up-regulated nicotine binding sites in rat striatal synaptosomes
64. 3H]metabolites in rat striatum by nicotinic drugs
65. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in Parkinsonian monkeys
66. Determination of amino acids in biological, pharmaceutical, plant and food samples by automated precolumn derivatization and high-performance liquid chromatography
67. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats
68. Synaptic relationship between dopaminergic afferents and cortical or thalamic input in the sensorimotor territory of the striatum of the monkey
69. Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: Role of glutamic acid
70. Effect of nicotine on levels of extracellular amino acids in regions of the rat brain in vivo
71. Smoking and Parkinson's disease
72. Nicotinic and muscarinc modulations of excitatory synaptic transmission in the rat pre-frontal cortex in vitro
73. Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors
74. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis
75. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations
76. Nicotinic cholinergic receptors in brain synaptosomes